Amol Akhade, MD, discusses the pharmacologic rationale for reduced-dose checkpoint inhibition and the funding barrier to definitive randomized evidence.
Amol Akhade, MD, MBBS
Advertisement
Articles by Amol Akhade, MD, MBBS
Amol Akhade, MD, discusses how cost shapes immunotherapy decisions and what standard cost-effectiveness measures miss for individual patients.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Sevabertinib for Advanced HER2 TKD–Mutated Nonsquamous NSCLC
2
TKD Mutation Status and CNS Data Guide Frontline Sequencing in HER2-Mutant NSCLC
3
Micvotabart Pelidotin Monotherapy Yields Responses in Pretreated Recurrent/Metastatic HNSCC
4
Durvalumab Plus Tarlatamab Boosts Survival as First-Line ES-SCLC Maintenance
5